Proactive Investors
19 Aug 2026, 06:45 UTC · 1h ago
Scancell secures UK clearance for late-stage melanoma trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
19 Aug 2026, 06:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Scancell Holdings PLC received UK MHRA approval to conduct a Phase III registrational trial for its lead melanoma drug, iSCIB1+. — Approval for a registrational trial is a critical regulatory milestone that directly precedes potential market approval and commercialization.
+0.80Zephyr Energy PLC has secured up to $15 million in non-dilutive financing for its Paradox Basin project, to be repaid via future production. — Non-dilutive funding allows the company to advance operations without reducing existing shareholder equity.
+0.50Scancell Holdings PLC is pursuing a proposed merger with US biotechnology company Neuphoria Therapeutics. — M&A activity generally suggests strategic expansion or valuation realization, though specific terms are not provided.
+0.40Continue reading
6 related stories
Search tags
The iSCIB1+ trial is expected to begin by the end of 2026, with initial survival data targeted for the second half of 2028. — Sets the timeline for the next major value-driving catalysts, though the window is several years away.
+0.20Which stocks this story touches
The company received UK regulatory approval to run a late-stage phase III trial for its lead melanoma drug.
The company secured up to $15 million in non-dilutive financing for its Paradox Basin project.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
